173 related articles for article (PubMed ID: 11259359)
1. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
Innocenti F; Iyer L; Ratain MJ
Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):596-600. PubMed ID: 11259359
[TBL] [Abstract][Full Text] [Related]
2. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
Iyer L; Hall D; Das S; Mortell MA; Ramírez J; Kim S; Di Rienzo A; Ratain MJ
Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924
[TBL] [Abstract][Full Text] [Related]
3. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
Iyer L; King CD; Whitington PF; Green MD; Roy SK; Tephly TR; Coffman BL; Ratain MJ
J Clin Invest; 1998 Feb; 101(4):847-54. PubMed ID: 9466980
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics: a tool for individualizing antineoplastic therapy.
Innocenti F; Iyer L; Ratain MJ
Clin Pharmacokinet; 2000 Nov; 39(5):315-25. PubMed ID: 11108431
[TBL] [Abstract][Full Text] [Related]
5. Paradoxical relationship between acetylator phenotype and amonafide toxicity.
Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Williams SF; Smiddy J
Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):573-9. PubMed ID: 1934870
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of amonafide dosing based on acetylator phenotype.
Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Vogelzang NJ; Lane LB
Cancer Res; 1993 May; 53(10 Suppl):2304-8. PubMed ID: 8485716
[TBL] [Abstract][Full Text] [Related]
7. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
Ratain MJ; Mick R; Janisch L; Berezin F; Schilsky RL; Vogelzang NJ; Kut M
Pharmacogenetics; 1996 Feb; 6(1):93-101. PubMed ID: 8845865
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer.
Araki K; Fujita K; Ando Y; Nagashima F; Yamamoto W; Endo H; Miya T; Kodama K; Narabayashi M; Sasaki Y
Cancer Sci; 2006 Nov; 97(11):1255-9. PubMed ID: 16965601
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
Innocenti F; Ratain MJ
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):52-5. PubMed ID: 12800608
[TBL] [Abstract][Full Text] [Related]
10. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity.
Iyer L; Das S; Janisch L; Wen M; Ramírez J; Karrison T; Fleming GF; Vokes EE; Schilsky RL; Ratain MJ
Pharmacogenomics J; 2002; 2(1):43-7. PubMed ID: 11990381
[TBL] [Abstract][Full Text] [Related]
11. Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk.
Lankisch TO; Schulz C; Zwingers T; Erichsen TJ; Manns MP; Heinemann V; Strassburg CP
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):695-701. PubMed ID: 18349289
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects.
Takeuchi K; Kobayashi Y; Tamaki S; Ishihara T; Maruo Y; Araki J; Mifuji R; Itani T; Kuroda M; Sato H; Kaito M; Adachi Y
J Gastroenterol Hepatol; 2004 Sep; 19(9):1023-8. PubMed ID: 15304120
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan.
Nagar S; Blanchard RL
Drug Metab Rev; 2006; 38(3):393-409. PubMed ID: 16877259
[TBL] [Abstract][Full Text] [Related]
14. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
Ratain MJ; Rosner G; Allen SL; Costanza M; Van Echo DA; Henderson IC; Schilsky RL
J Clin Oncol; 1995 Mar; 13(3):741-7. PubMed ID: 7884434
[TBL] [Abstract][Full Text] [Related]
15. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports.
Wasserman E; Myara A; Lokiec F; Goldwasser F; Trivin F; Mahjoubi M; Misset JL; Cvitkovic E
Ann Oncol; 1997 Oct; 8(10):1049-51. PubMed ID: 9402181
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and anticancer activities of 6-amino amonafide derivatives.
Norton JT; Witschi MA; Luong L; Kawamura A; Ghosh S; Stack MS; Sim E; Avram MJ; Appella DH; Huang S
Anticancer Drugs; 2008 Jan; 19(1):23-36. PubMed ID: 18043127
[TBL] [Abstract][Full Text] [Related]
18. Rapid allelic discrimination by TaqMan PCR for the detection of the Gilbert's syndrome marker UGT1A1*28.
Ehmer U; Lankisch TO; Erichsen TJ; Kalthoff S; Freiberg N; Wehmeier M; Manns MP; Strassburg CP
J Mol Diagn; 2008 Nov; 10(6):549-52. PubMed ID: 18832463
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question.
Deeken JF; Slack R; Marshall JL
Cancer; 2008 Oct; 113(7):1502-10. PubMed ID: 18720361
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics of irinotecan.
Toffoli G; Cecchin E; Corona G; Boiocchi M
Curr Med Chem Anticancer Agents; 2003 May; 3(3):225-37. PubMed ID: 12769780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]